




LFW

PATENT
Docket No. 524522000500

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA, 22313-1450, on August 4, 2004.


Laura L. Shires

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Arturo J. ANGEL et al.

Serial No.: 10/655,911

Filing Date: September 5, 2003

For: COMPOSITIONS AND KITS FOR THE
REMOVAL OF IRRITATING
COMPOUNDS FROM BODILY
SURFACES

Examiner: Not Yet Assigned

Group Art Unit: 1615

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are not submitted. Copies of non-patent literature are submitted herewith. The Examiner is requested to make these documents of record in the application.

The documents listed on the attached Form PTO-1449 were cited in an International Search Report mailed on June 30, 2004 (copy attached) directed to a counterpart international or foreign application. A certification under 37 C.F.R. § 1.97(e)(1) follows:

I hereby certify that each item of information was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.


In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 524522000500. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: August 4, 2004

Respectfully submitted,

By: Jill A. Jacobson
Jill A. Jacobson
Registration No. 40,030

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5876
Facsimile: (650) 494-0792



PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/655,911	
	Filing Date	September 5, 2003	
	First Named Inventor	Arturo J. ANGEL	
	Art Unit	1615	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	8 + 15 refs.	Attorney Docket Number	524522000500

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement, Supplemental (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO-1449 + copy (4 pages) 2. Fifteen (15) references 3. Return postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP (Customer No. 25226) Jill A. Jacobson - 40,030
Signature	<i>Jill A. Jacobson</i>
Date	August 4, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: August 4, 2004	Signature: <i>Laura L. Shires</i> (Laura L. Shires)

Form PTO-1449

Docket Number 524522000500

Application Number 10/655,911

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Arturo J. ANGEL et al.

Filing Date September 5, 2003

Group Art Unit 1615

Mailing Date August 4, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	01/15/1985	4,493,848	LaHann et al.			
	2.	10/27/1998	5,827,886	Hersh			
	3.	01/05/1999	5,856,361	Holt et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	4.	Allen, L.V. (November, 1998). "Coumarin: Agent With Many Uses," <i>U.S. Pharm.</i> 23:106-108.
	5.	British Industrial Biological Research Association (1991). "Toxicity Profile: Polyethylene Glycol 300 (PEG 300)," <i>British Industrial Biological Research Association Government Reports Announcements and Index</i> , 19:1-5.
	6.	Edlich, R.F. et al. (November 6, 2003). "Burns, Chemical" located at < http://www.emedicine.com/plastic/topic492.html > last visited on July 6, 2004, 17 pages.
	7.	Hemker, W. (November, 1991). "Universal oil-in-water Polyelectrolyte Emulsifiers for Advanced Cosmetic Product Formulation," <i>Parfümerie und Kosmetik</i> 72:730-741.
	8.	International Search Report mailed on June 30, 2004, for PCT Patent Application No. PCT/US03/27742 filed on September 5, 2003, 6 pages.
	9.	Knezevic, D.L. et al. (1992). "Efficacy of Different Formulations of Protective Ointments in Animals Percutaneously Poisoned With Highly Toxic Organophosphates," <i>Arch. Farm.</i> 42(4-5):119-126.(English summary.)
	10.	Laws, R. et al. (November 12, 2002). "Burns, Chemical" located at < http://www.emedicine.com/derm/topic777.html > last visited on July 6, 2004, 14 pages.
	11.	Leber, A.P. et al. (1990). "Triethylene Glycol Ethers: Evaluations of In Vitro Absorption Through Human Epidermis, 21-Day Dermal Toxicity in Rabbits, and a Developmental Toxicity Screen in Rats," <i>J. Am. Coll. Toxicol.</i> 9(5):507-515.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 524522000500	Application Number 10/655,911
	Applicant Arturo J. ANGEL et al.	
	Filing Date September 5, 2003	Group Art Unit 1615
	Mailing Date August 4, 2004	

12.	Lee, D.C. et al. (June, 2003). "Magnesium-Aluminum Hydroxide Suspension For The Treatment of Dermal Capsaicin Exposures," <i>Acad. Emerg. Med.</i> 10(6):688-690.
13.	Miller, C.H. (1994). "Inhibition of NNK Mutagenesis and Metabolism by Chemopreventive Phytochemicals (Tobacco, Nitrosamines)," Abstract, <i>Diss. Abstr. Int. (B)</i> 55(6):2219.
14.	Olson, C.T. et al. (1991). "Evaluation of Compounds as Barriers to Dermal Penetration of Organophosphates Using Acetylcholinesterase Inhibition," <i>Toxicology Letters</i> 55:325-334.
15.	Osol, A. et al. eds. (1975). <u>Remington's Pharmaceutical Sciences</u> 15th Edition, Mack Publishing Co.: Easton, PA p. xi (Table of Contents Only.)
16.	Roberts, M.S. et al. (1977). "Permeability of Human Epidermis to Phenolic Compounds," <i>J. Pharm. Pharmacol.</i> 29:677-683.
17.	Roberts, M.S. et al. (1978). "The Percutaneous Absorption of Phenolic Compounds: The Mechanism of Diffusion Across the Stratum Corneum," <i>J. Pharm. Pharmacol.</i> 30:486-490.
18.	Zatz, J.L. et al. (Sept.-Oct. 1983). "Evaluation of Solvent-Skin Interaction in Percutaneous Absorption," <i>J. Soc. Cosmet. Chem.</i> 34:327-334.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.